Randox Cystatin C facilitates early detection and treatment of chronic kidney disease

As a more sensitive maker of renal dysfunction Randox Cystatin C offers several advantages over traditional creatinine assays. Unlike creatinine tests, Randox Cystatin C is virtually unaffected by non-renal factors including muscle mass, weight, height, age, gender, diet and drugs. This makes it particularly useful in cases where creatinine measurement is not appropriate e.g. in individuals who are obese, malnourished, who have liver disease or in infants and the elderly.

An additional benefit delivered by Randox Cystatin C is that it facilitates the early detection and treatment of chronic kidney disease due to the fact Cystatin C is highly sensitive to even small changes in Glomerular Filtration Rate (GFR). Furthermore, Randox Cystatin C does not suffer from a 'blind area', like creatinine based testing. The 'blind range' associated with creatinine testing can mean a high percentage of kidney function is lost before elevation of this analyte occurs. Randox Cystatin C however, is capable of detecting early reductions in GFR, therefore providing more accurate results and supporting the prompt treatment of kidney disease.

Randox Cystatin C Key Assay Details

•Liquid ready-to-use reagents
•Latex enhanced immunoturbidimetric assay
•Extensive measuring range- 0.4-10mg/l
•On-board stability of 28 days at +10°C
•Instrument Specific Applications available for an extensive range of clinical chemistry analyzers

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Randox Laboratories Ltd.. (2019, June 19). Randox Cystatin C facilitates early detection and treatment of chronic kidney disease. News-Medical. Retrieved on December 26, 2024 from https://www.news-medical.net/news/20140722/Randox-Cystatin-C-facilitates-early-detection-and-treatment-of-chronic-kidney-disease.aspx.

  • MLA

    Randox Laboratories Ltd.. "Randox Cystatin C facilitates early detection and treatment of chronic kidney disease". News-Medical. 26 December 2024. <https://www.news-medical.net/news/20140722/Randox-Cystatin-C-facilitates-early-detection-and-treatment-of-chronic-kidney-disease.aspx>.

  • Chicago

    Randox Laboratories Ltd.. "Randox Cystatin C facilitates early detection and treatment of chronic kidney disease". News-Medical. https://www.news-medical.net/news/20140722/Randox-Cystatin-C-facilitates-early-detection-and-treatment-of-chronic-kidney-disease.aspx. (accessed December 26, 2024).

  • Harvard

    Randox Laboratories Ltd.. 2019. Randox Cystatin C facilitates early detection and treatment of chronic kidney disease. News-Medical, viewed 26 December 2024, https://www.news-medical.net/news/20140722/Randox-Cystatin-C-facilitates-early-detection-and-treatment-of-chronic-kidney-disease.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Randox expand range of immunoturbidimetric proteins